Figure 6

Effects of AZD6244 and/or BEZ235 on the expressions of Ki-67 (A) and CD31 (B) in NCI-1993, NCI-1975 and NCI-H460 xenograft models. All three gefitinib-resistant tumor xenograft models were treated with the AZD6244 and/or BEZ235 for 2 h on Day 21 of the efficacy study, tumor tissues in each group were resected and immunostained with anti-Ki67 and anti-CD31 antibodies. N = 10, *, P < 0.05 vs vehicle group. **, P < 0.01 vs vehicle group.